Skip to main content

AS/Spondyloarthritis

AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality.https://t.co/bi3q7LW4S6 https://t.co/DUc9sB4MI0
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx
AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality.https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD
RheumNow Podcast square

PsA Til Death Do Us Part (1.20.2023)

Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article
death

AS, but not PsA, has Increased Mortality Risk

Jan 19, 2023

Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease. A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA

Read Article
SPA.spectrum.jpg

Phase III Trials Back Bimekizumab for Spondyloarthritis

Medpage Today
Jan 19, 2023

Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.

Read Article
Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS https://t.co/GsTwHbXVLm https://t.co/22i3yskUpA
Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at baseline. Pts w/ enthesitis had worse pain, BASDAI, mBASDAI, ASDAS-CRP scores & after 2 yrs had fewer in low dz state (16 vs 31.5%) https://t.co/sChQ4WFmlW https://t.co/BkjzxCQIGF
How would you treat 37yoF B27+ AS on Taltz, now pregnant?(Failed NSAIDs, TNFi's)
RheumNow Podcast square

Rheum Believe it Or Not (1.13.2023)

Jan 13, 2023

Dr. Jack Cush reviews the notable standouts in the news since the 1st of January.  Surprising reports on ferritin, alcohol benefits, cannabis for pain and a lower dementia risk with hydroxychloroquine.  Here are the links below.




  1. ACR GCA classification criteria tested in 676

Read Article
Treatment Considerations in Axial Spondyloarthritis https://t.co/GRQfk4B4QN https://t.co/xX5AYAD90c
For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered. RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually!https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd
2022,wordle

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f
Many have quoted and shown this image of Ankylosing Spondylitis in a young military recruit at age 25, 35, 45, 50 & 51yrs. This may be the MOST used slide in rheum! It comes from the work of Toronto's Dr. Hugh Little, who sadly passed away at age 58 yrs. https… https://t.co/G28YlyhX3v
RheumNow Podcast square

Best of 2022: EULAR 2022 Top 10 Abstracts

Dec 23, 2022

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…

Read Article
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/Kc1n4RVe3v
The First Head to Head trial in Axial SpA Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H
RheumNow Podcast square

Fever, FROST, & Pericarditis (12.16.2022)

Dec 16, 2022

Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK".




  1. During 2021–22 FLU season, 6% of hosp pedi-influenza pts had SARS-CoV-2 coinfection; these required more respiratory support. Risk of

Read Article
Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. https://t.co/dCLlgiGV9K https://t.co/a4iI1q3zZC
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
×